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CASE STUDY
The simultaneous destruction of skeletal muscle cells with the 
consequent release of cellular contents into the circulatory system 
is called rhabdomyolysis and can be triggered by mechanical injury, 
ischaemia, infections, or genetic alterations to drugs and toxins.1 The 
intrinsic characteristics of muscle tissue make it especially vulnerable 
to drug-related cell damage. Although rare, the life-threatening 
illness of acute steroid myopathy causing rhabdomyolysis in patients 
on high-dose corticosteroids should be recognised by clinicians and 
sports medicine specialists.
This article presents the case of a young golf player with 
rhabdomyolysis, as well as current theories on cellular mechanisms, 
and symptoms and treatment of acute corticosteroid-induced 
rhabdomyolysis.
Case report
A 27-year-old professional golf player presented with neck and back 
pain suggestive of an inflammatory arthropathy. Symptoms included 
polyarthralgia of the elbows, shoulders, knees and right foot as well 
as morning stiffness for longer than one hour. The morning stiffness 
and polyarthritis responded to anti-inflammatory drugs. 
On physical examination he had a normal Schober test and chest 
expansion. While systemic and neurological examination was normal, 
the FABER test was positive bilaterally with tenderness of the sacro-
iliac (SI) joints and thoracic spinous processes. The initial differential 
diagnosis included possible spondylarthropathy, and mechanical neck 
and back pain.
Further tests revealed a normal full blood count. Erythrocyte 
sedimentation rate was 2 mm/h and C-reactive protein levels were 
2 mg/l. HLA B27, rheumatoid factor and anti-cyclical citrillunated 
peptide antibody tests were negative. The isotope bone scan reported 
low-grade inflammatory changes in the superior part of the SI joints 
and normal uptake in the spine and peripheral joints. The lumbar 
spine radiograph showed slight degeneration of the L5/S1 facet joints. 
The neck radiograph showed torticollis, while the thoracic spine 
radiograph showed kyphosis.
Having failed to respond to physiotherapy and anti-inflammatory 
drugs, he was admitted to hospital for a trial of intravenous 
therapeutic agents. A high dose of intravenous cortisone (125 
mg methylprednisolone twice daily) was infused, backache 
of inflammatory origin typically responding to this form of 
management. The baseline creatine kinase (CK) level was 67 IU/l. 
The following day (day 2 of hospital admission) the patient had 
generalised myalgia and stiffness. CK levels were elevated at 1 568 
IU/l and myoglobin at 448 mg/ml. Phosphate, magnesium and 
electrolyte levels were normal, as was troponin T. Thyroid function 
was also normal and the patient’s history and clinical course were 
not supportive of metabolic myopathy. The patient also denied any 
changes in his training programme, the use of drugs such as statins 
or colchisine, nutritional supplementation or exposure to toxins such 
as snake venom. Therefore all other possible causes for the elevated 
CK and myoglobin levels were eliminated.
On day 3 of hospital admission, the patient’s CK was markedly 
elevated at 4 609 IU/l and the myoglobin was 1 566 ng/ml. He was 
treated with intravenous fluid, sodium bicarbonate and mannitol to 
prevent renal failure and arrhythmias due to increased potassium 
levels. The cortisone treatment was also discontinued. On the fourth 
day of hospitalisation the CK level was 8 030 IU/l and the myoglobin 
172 mg/ml. On day 5 the levels decreased to 3 301 IU/l and 129 mg/ml, 
respectively (the second day after cortisone treatment was stopped). 
The diagnosis of acute steroid-induced rhabdomyolysis was based 
on the combination of symptoms and biochemical markers with 
subsequent clearance of both after cessation of steroid therapy. 
Discussion
The association between high-dose corticosteroid administration 
and muscle weakness was first reported by Cushing in 1932.2 
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Corticosteroid-induced myopathy is a disease that mainly causes 
weakness of the proximal muscles of the upper and lower limbs 
and the neck flexors.3 It is caused by an excess of corticosteroids 
from endogenous or exogenous sources such as adrenal tumours 
or steroid treatment. There are two distinct types of corticosteroid-
induced myopathy, namely chronic and acute,3 which may pose the 
risk of rhabdomyolysis development. The chronic type of myopathy 
is caused by prolonged exposure to corticosteroids, while the 
acute type is less common and occurs abruptly when the patient is 
receiving high doses of corticosteroids. Previous cases of myopathy 
have been reported in patients receiving cortisone treatment for 
acute asthma,2  patients with phaeochromocytoma,4 and those in 
intensive care units.5
Acute myopathy induced by high-dose corticosteroid treatment 
differs significantly from chronic myopathy. This suggests a different 
pathogenesis.2 Willams et al.2 described the main differences between 
chronic and acute myopathy as listed in Table 1.
Cellular mechanism of rhabdomyolysis
The specific physiological mechanisms by which the different drugs 
act during rhabdomyolysis are uncertain.3,6 Current research suggests 
that several factors play a role in the development of rhabdomyolysis, 
such as decreased protein synthesis and sarcolemmal excitability, 
increased protein degradation, modifications in carbohydrate 
metabolism, mitochondrial changes and electrolyte disturbances. 
Steve Lim (2010) suggests that the use of fluorinated steroids such 
as dexamethasone or triamcinolone more frequently causes steroid 
myopathy than non-fluorinated steroids such as prednisone or 
hydrocortisone.3 Muscles that are less active are more likely to be 
affected by corticosteroid, meaning that a sedentary lifestyle may 
increase the risk of muscle weakness.3,5 Interestingly, gender also 
seems to be a risk, as women are twice as likely as men to develop 
muscle weakness.4
Martin Hohenegger6 described the cellular mechanism by which 
rhabdomyolysis develops. It begins with a decrease in intracellular 
ATP and a simultaneous increase in myoplasmic calcium (Ca2+) 
concentrations.6 This leads to a deficiency in ATP supplied by 
the mitochondrial chain, leading to reduced replenishment 
of Ca2+ stores and extrusion of Ca2+ to the extracellular space.6 
Calpain proteases are activated by the long-term elevated Ca2+ 
levels that further degrade the proteins participating in Ca2+ 
homeostasis. This intensifies the myoplasmic Ca2+ overload.7 
High cytosolic calcium has various detrimental effects. Firstly, 
the mitochondria are overcome, leading to the disruption of 
oxidative phosphorylation, which decreases the available ATP. 
Secondly, apoptosis is triggered by the increased production of 
reactive oxygen species by the mitochondria, leading to the free 
radical disruption of cell and organelle membranes. Thirdly, a 
series of proteases and phospholipases are activated, damaging 
the myofibrillar network.1
Symptoms and treatment
Rhabdomyolysis is preceded by muscle weakness, muscle stiffness, 
symptoms of myalgia, swelling, tenderness and tea-coloured 
urine.1 There are, however, no clear laboratory parameters that 
estimate the risk a patient has of developing rhabdomyolysis,6 and 
a single symptom is not enough to make a definite diagnosis of 
rhabdomyolysis. Clinicians should be alert to the presence of the 
following possible indicators:1 
• A serum CK level >1 000 U/l is important in determining 
whether the patient is suffering from rhabdomyolysis.1 Typically, 
the serum concentration of CK rises in the first 12 hours after 
injury, peaks at 3 days, and normalises at approximately 5 days.1 
• Damaged muscles rapidly release myoglobin, leading to 
elevated serum and urinary myoglobin concentrations. Levels 
peak at 8 - 12 hours, but typically normalise in serum within 
24 hours.1 This was also found in our patient.
• A urine dipstick will indicate 'blood' in the urine, indicating 
presence in this case of myoglobin (not haemoglobin). As such, 
a combination of myoglobinuria and elevated plasma CK levels 
confirms the diagnosis of rhabdomyolysis.1
• Electrolyte  abnormalit ies  such as  hyperkalaemia, 
hyperphosphataemia and hypocalcaemia occur, but are not 
specific enough for diagnostic certainty.1
Administration of the rhabdomyolysing agents/medication should 
be stopped immediately to prevent further skeletal muscle damage.6 
Control of fluid equilibrium is vital to stabilise the circulation and 
serum potassium and to prevent acidosis.1,6 After the corticosteroid 
dose is reduced or discontinued, the steroid-induced muscle weakness 
decreases, although it can take weeks or months for full recovery.3
Conclusion
Acute corticosteroid-induced rhabdomyolysis is rare but potentially 
life-threatening. Early diagnosis is vital in minimising the secondary 
damage. 
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Table 1. Main differences between chronic and acute myopathy
Chronic myopathy Acute myopathy
Muscle weakness Proximal muscles Proximal and distal muscles
CK levels Normal/slightly elevated Significantly higher, possible rhabdomyolysis
Muscle biopsy Type IIB fibre atrophy Focal and diffuse necrosis
